Single pass tangential flow filtration to debottleneck downstream processing for therapeutic antibody production

As the therapeutic monoclonal antibody (mAb) market continues to grow, optimizing production processes is becoming more critical in improving efficiencies and reducing cost‐of‐goods in large‐scale production. With the recent trends of increasing cell culture titers from upstream process improvements...

Full description

Saved in:
Bibliographic Details
Published inBiotechnology and bioengineering Vol. 109; no. 4; pp. 962 - 970
Main Authors Dizon-Maspat, Jemelle, Bourret, Justin, D'Agostini, Anna, Li, Feng
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.04.2012
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract As the therapeutic monoclonal antibody (mAb) market continues to grow, optimizing production processes is becoming more critical in improving efficiencies and reducing cost‐of‐goods in large‐scale production. With the recent trends of increasing cell culture titers from upstream process improvements, downstream capacity has become the bottleneck in many existing manufacturing facilities. Single Pass Tangential Flow Filtration (SPTFF) is an emerging technology, which is potentially useful in debottlenecking downstream capacity, especially when the pool tank size is a limiting factor. It can be integrated as part of an existing purification process, after a column chromatography step or a filtration step, without introducing a new unit operation. In this study, SPTFF technology was systematically evaluated for reducing process intermediate volumes from 2× to 10× with multiple mAbs and the impact of SPTFF on product quality, and process yield was analyzed. Finally, the potential fit into the typical 3‐column industry platform antibody purification process and its implementation in a commercial scale manufacturing facility were also evaluated. Our data indicate that using SPTFF to concentrate protein pools is a simple, flexible, and robust operation, which can be implemented at various scales to improve antibody purification process capacity. Biotechnol. Bioeng. 2012; 109:962–970. © 2011 Wiley Periodicals, Inc. Single Pass Tangential Flow Filtration (SPTFF) is an emerging technology, which is potentially useful in debottlenecking downstream capacity, especially when the pool tank size is a limiting factor. In this study, SPTFF technology was systematically evaluated for reducing process intermediate volumes from 2× to 10× with multiple mAbs and the impact of SPTFF on product quality, and process yield was analyzed.
AbstractList As the therapeutic monoclonal antibody (mAb) market continues to grow, optimizing production processes is becoming more critical in improving efficiencies and reducing cost-of-goods in large-scale production. With the recent trends of increasing cell culture titers from upstream process improvements, downstream capacity has become the bottleneck in many existing manufacturing facilities. Single Pass Tangential Flow Filtration (SPTFF) is an emerging technology, which is potentially useful in debottlenecking downstream capacity, especially when the pool tank size is a limiting factor. It can be integrated as part of an existing purification process, after a column chromatography step or a filtration step, without introducing a new unit operation. In this study, SPTFF technology was systematically evaluated for reducing process intermediate volumes from 2x to 10x with multiple mAbs and the impact of SPTFF on product quality, and process yield was analyzed. Finally, the potential fit into the typical 3-column industry platform antibody purification process and its implementation in a commercial scale manufacturing facility were also evaluated. Our data indicate that using SPTFF to concentrate protein pools is a simple, flexible, and robust operation, which can be implemented at various scales to improve antibody purification process capacity. [PUBLICATION ABSTRACT]
As the therapeutic monoclonal antibody (mAb) market continues to grow, optimizing production processes is becoming more critical in improving efficiencies and reducing cost-of-goods in large-scale production. With the recent trends of increasing cell culture titers from upstream process improvements, downstream capacity has become the bottleneck in many existing manufacturing facilities. Single Pass Tangential Flow Filtration (SPTFF) is an emerging technology, which is potentially useful in debottlenecking downstream capacity, especially when the pool tank size is a limiting factor. It can be integrated as part of an existing purification process, after a column chromatography step or a filtration step, without introducing a new unit operation. In this study, SPTFF technology was systematically evaluated for reducing process intermediate volumes from 2× to 10× with multiple mAbs and the impact of SPTFF on product quality, and process yield was analyzed. Finally, the potential fit into the typical 3-column industry platform antibody purification process and its implementation in a commercial scale manufacturing facility were also evaluated. Our data indicate that using SPTFF to concentrate protein pools is a simple, flexible, and robust operation, which can be implemented at various scales to improve antibody purification process capacity.
Abstract As the therapeutic monoclonal antibody (mAb) market continues to grow, optimizing production processes is becoming more critical in improving efficiencies and reducing cost‐of‐goods in large‐scale production. With the recent trends of increasing cell culture titers from upstream process improvements, downstream capacity has become the bottleneck in many existing manufacturing facilities. Single Pass Tangential Flow Filtration (SPTFF) is an emerging technology, which is potentially useful in debottlenecking downstream capacity, especially when the pool tank size is a limiting factor. It can be integrated as part of an existing purification process, after a column chromatography step or a filtration step, without introducing a new unit operation. In this study, SPTFF technology was systematically evaluated for reducing process intermediate volumes from 2× to 10× with multiple mAbs and the impact of SPTFF on product quality, and process yield was analyzed. Finally, the potential fit into the typical 3‐column industry platform antibody purification process and its implementation in a commercial scale manufacturing facility were also evaluated. Our data indicate that using SPTFF to concentrate protein pools is a simple, flexible, and robust operation, which can be implemented at various scales to improve antibody purification process capacity. Biotechnol. Bioeng. 2012; 109:962–970. © 2011 Wiley Periodicals, Inc.
As the therapeutic monoclonal antibody (mAb) market continues to grow, optimizing production processes is becoming more critical in improving efficiencies and reducing cost‐of‐goods in large‐scale production. With the recent trends of increasing cell culture titers from upstream process improvements, downstream capacity has become the bottleneck in many existing manufacturing facilities. Single Pass Tangential Flow Filtration (SPTFF) is an emerging technology, which is potentially useful in debottlenecking downstream capacity, especially when the pool tank size is a limiting factor. It can be integrated as part of an existing purification process, after a column chromatography step or a filtration step, without introducing a new unit operation. In this study, SPTFF technology was systematically evaluated for reducing process intermediate volumes from 2× to 10× with multiple mAbs and the impact of SPTFF on product quality, and process yield was analyzed. Finally, the potential fit into the typical 3‐column industry platform antibody purification process and its implementation in a commercial scale manufacturing facility were also evaluated. Our data indicate that using SPTFF to concentrate protein pools is a simple, flexible, and robust operation, which can be implemented at various scales to improve antibody purification process capacity. Biotechnol. Bioeng. 2012; 109:962–970. © 2011 Wiley Periodicals, Inc. Single Pass Tangential Flow Filtration (SPTFF) is an emerging technology, which is potentially useful in debottlenecking downstream capacity, especially when the pool tank size is a limiting factor. In this study, SPTFF technology was systematically evaluated for reducing process intermediate volumes from 2× to 10× with multiple mAbs and the impact of SPTFF on product quality, and process yield was analyzed.
Author Dizon-Maspat, Jemelle
Li, Feng
Bourret, Justin
D'Agostini, Anna
Author_xml – sequence: 1
  givenname: Jemelle
  surname: Dizon-Maspat
  fullname: Dizon-Maspat, Jemelle
  organization: Oceanside Pharma Technical Development, Genentech, Inc., 1 Antibody Way, Oceanside, California 92056; telephone: 8610-59755449; fax: 8610-59755423
– sequence: 2
  givenname: Justin
  surname: Bourret
  fullname: Bourret, Justin
  organization: Oceanside Pharma Technical Development, Genentech, Inc., 1 Antibody Way, Oceanside, California 92056; telephone: 8610-59755449; fax: 8610-59755423
– sequence: 3
  givenname: Anna
  surname: D'Agostini
  fullname: D'Agostini, Anna
  organization: Oceanside Pharma Technical Development, Genentech, Inc., 1 Antibody Way, Oceanside, California 92056; telephone: 8610-59755449; fax: 8610-59755423
– sequence: 4
  givenname: Feng
  surname: Li
  fullname: Li, Feng
  email: li.feng@mab-works.com
  organization: Oceanside Pharma Technical Development, Genentech, Inc., 1 Antibody Way, Oceanside, California 92056; telephone: 8610-59755449; fax: 8610-59755423
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22094920$$D View this record in MEDLINE/PubMed
BookMark eNp9kU1v1DAQhi1URLeFA38AWVyAQ1p_xY6PUEGpWgHSLkLiYjnJpLjN2sF2tOy_x8u2PSDBaTTSM8_o1XuEDnzwgNBzSk4oIey0dfmECa7UI7SgRKuKME0O0IIQIitea3aIjlK6KatqpHyCDhkjWmhGFmhaOn89Ap5sSjhbfw0-OzviYQwbPLgxR5td8DgH3EMbch7BQ3eL-7DxKUewazzF0EFKxYOHEHH-AdFOMGfXYVtkbei3O6afu53pKXo82DHBs7t5jL5-eL86-1hdfT6_OHt7VXWiLgksJbKE0LIBKUSvoGe97aHjUjSshbahQheOWN7VVg2dog30lspay3qwRPFj9GrvLa9_zpCyWbvUwThaD2FORjNeK6G0LOTr_5JUcEFYzSkt6Mu_0JswR19yFJ9sCOWNKNCbPdTFkFKEwUzRrW3cGkrMri9T-jJ_-irsizvh3K6hfyDvCyrA6R7YuBG2_zaZdxere2W1v3Apw6-HCxtvjVRc1ebbp3OzvPy-_HJZlhX_DUhysYY
CODEN BIBIAU
CitedBy_id crossref_primary_10_1080_14712598_2020_1693541
crossref_primary_10_1016_j_cherd_2022_04_003
crossref_primary_10_1002_biot_202000309
crossref_primary_10_1016_j_memsci_2023_121633
crossref_primary_10_1080_19420862_2017_1417717
crossref_primary_10_1002_biot_201700740
crossref_primary_10_1002_bit_27733
crossref_primary_10_3390_pr7060317
crossref_primary_10_1002_btpr_2671
crossref_primary_10_3390_pr7110781
crossref_primary_10_1002_biot_202100351
crossref_primary_10_1016_j_seppur_2022_120949
crossref_primary_10_3389_fchem_2018_00454
crossref_primary_10_1016_j_memsci_2016_11_007
crossref_primary_10_1016_j_memsci_2021_119606
crossref_primary_10_1002_btpr_2601
crossref_primary_10_1002_btpr_3378
crossref_primary_10_1021_acs_oprd_2c00291
crossref_primary_10_1002_bit_24955
crossref_primary_10_1002_btpr_2763
crossref_primary_10_1002_btpr_3456
crossref_primary_10_1016_j_coche_2015_07_005
crossref_primary_10_1016_j_jchromb_2023_123919
crossref_primary_10_1111_imr_13107
crossref_primary_10_1016_j_seppur_2022_120776
crossref_primary_10_1016_j_jbiotec_2015_06_393
crossref_primary_10_1002_bit_27233
crossref_primary_10_1002_bit_25695
crossref_primary_10_1016_j_addr_2021_04_027
crossref_primary_10_1016_j_memsci_2016_02_031
crossref_primary_10_1016_j_memsci_2021_120047
crossref_primary_10_1146_annurev_chembioeng_092220_125832
crossref_primary_10_1007_s00449_021_02683_8
crossref_primary_10_1016_j_coche_2018_08_005
crossref_primary_10_1016_j_chroma_2022_463040
crossref_primary_10_1016_j_memsci_2020_118695
crossref_primary_10_1016_j_procbio_2022_01_017
crossref_primary_10_3390_bioengineering1040213
crossref_primary_10_1016_j_seppur_2021_119987
crossref_primary_10_1186_s13287_021_02319_4
crossref_primary_10_1002_btpr_2862
crossref_primary_10_1002_btpr_3353
crossref_primary_10_1016_j_biologicals_2019_09_007
crossref_primary_10_1002_bit_26708
crossref_primary_10_1016_j_memsci_2021_119396
crossref_primary_10_1016_j_partic_2019_06_004
crossref_primary_10_3390_v13020268
crossref_primary_10_1016_j_memsci_2020_118804
crossref_primary_10_1016_j_jbiotec_2021_10_003
crossref_primary_10_1002_biot_202300194
crossref_primary_10_1016_j_ymthe_2018_09_015
crossref_primary_10_1016_j_chroma_2013_11_039
crossref_primary_10_1016_j_memsci_2019_117517
Cites_doi 10.1002/btpr.404
10.1021/jp9001548
10.1016/j.memsci.2007.02.045
10.1021/bp070117s
10.1016/j.jchromb.2006.10.033
10.1002/jps.21322
ContentType Journal Article
Copyright Copyright © 2011 Wiley Periodicals, Inc.
Copyright John Wiley and Sons, Limited Apr 2012
Copyright_xml – notice: Copyright © 2011 Wiley Periodicals, Inc.
– notice: Copyright John Wiley and Sons, Limited Apr 2012
DBID BSCLL
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QF
7QO
7QQ
7SC
7SE
7SP
7SR
7T7
7TA
7TB
7U5
8BQ
8FD
C1K
F28
FR3
H8D
H8G
JG9
JQ2
KR7
L7M
L~C
L~D
P64
7X8
DOI 10.1002/bit.24377
DatabaseName Istex
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Aluminium Industry Abstracts
Biotechnology Research Abstracts
Ceramic Abstracts
Computer and Information Systems Abstracts
Corrosion Abstracts
Electronics & Communications Abstracts
Engineered Materials Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Materials Business File
Mechanical & Transportation Engineering Abstracts
Solid State and Superconductivity Abstracts
METADEX
Technology Research Database
Environmental Sciences and Pollution Management
ANTE: Abstracts in New Technology & Engineering
Engineering Research Database
Aerospace Database
Copper Technical Reference Library
Materials Research Database
ProQuest Computer Science Collection
Civil Engineering Abstracts
Advanced Technologies Database with Aerospace
Computer and Information Systems Abstracts – Academic
Computer and Information Systems Abstracts Professional
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Materials Research Database
Technology Research Database
Computer and Information Systems Abstracts – Academic
Mechanical & Transportation Engineering Abstracts
ProQuest Computer Science Collection
Computer and Information Systems Abstracts
Materials Business File
Environmental Sciences and Pollution Management
Aerospace Database
Copper Technical Reference Library
Engineered Materials Abstracts
Biotechnology Research Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Advanced Technologies Database with Aerospace
ANTE: Abstracts in New Technology & Engineering
Civil Engineering Abstracts
Aluminium Industry Abstracts
Electronics & Communications Abstracts
Ceramic Abstracts
METADEX
Biotechnology and BioEngineering Abstracts
Computer and Information Systems Abstracts Professional
Solid State and Superconductivity Abstracts
Engineering Research Database
Corrosion Abstracts
MEDLINE - Academic
DatabaseTitleList Engineering Research Database
MEDLINE - Academic
CrossRef
MEDLINE

Materials Research Database
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
Chemistry
Biology
Anatomy & Physiology
EISSN 1097-0290
EndPage 970
ExternalDocumentID 2604783931
10_1002_bit_24377
22094920
BIT24377
ark_67375_WNG_SKZSPK75_T
Genre article
Evaluation Studies
Journal Article
Feature
GroupedDBID ---
-~X
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
23N
31~
33P
3EH
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABPVW
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACIWK
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AI.
AIAGR
AITYG
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AUFTA
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BLYAC
BMNLL
BMXJE
BNHUX
BROTX
BRXPI
BSCLL
BY8
CS3
D-E
D-F
DCZOG
DPXWK
DR1
DR2
DRFUL
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
G-S
G.N
GNP
GODZA
H.T
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LH6
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MXFUL
MXSTM
N04
N05
N9A
NDZJH
NF~
NNB
O66
O9-
OIG
P2P
P2W
P2X
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RBB
RIWAO
RJQFR
RNS
ROL
RWI
RX1
RYL
SAMSI
SUPJJ
SV3
TN5
UB1
V2E
VH1
W8V
W99
WBKPD
WH7
WIB
WIH
WIK
WJL
WNSPC
WOHZO
WQJ
WRC
WSB
WXSBR
WYISQ
XG1
XPP
XSW
XV2
Y6R
ZGI
ZXP
ZZTAW
~02
~IA
~KM
~WT
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QF
7QO
7QQ
7SC
7SE
7SP
7SR
7T7
7TA
7TB
7U5
8BQ
8FD
C1K
F28
FR3
H8D
H8G
JG9
JQ2
KR7
L7M
L~C
L~D
P64
7X8
ID FETCH-LOGICAL-c4597-a106290968e644d7ed2dadec36482beb81495970a3c5a7fc718eda165965fa073
IEDL.DBID DR2
ISSN 0006-3592
IngestDate Fri Aug 16 08:58:17 EDT 2024
Fri Aug 16 21:13:34 EDT 2024
Thu Oct 10 17:12:18 EDT 2024
Fri Aug 23 03:03:38 EDT 2024
Sat Sep 28 07:49:36 EDT 2024
Sat Aug 24 01:06:04 EDT 2024
Wed Oct 30 09:48:54 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
License Copyright © 2011 Wiley Periodicals, Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4597-a106290968e644d7ed2dadec36482beb81495970a3c5a7fc718eda165965fa073
Notes ark:/67375/WNG-SKZSPK75-T
istex:B5B05F3E8BA7636FB4CBCF134037E1445791432C
ArticleID:BIT24377
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 22094920
PQID 926801384
PQPubID 48814
PageCount 9
ParticipantIDs proquest_miscellaneous_923574796
proquest_miscellaneous_1434025311
proquest_journals_926801384
crossref_primary_10_1002_bit_24377
pubmed_primary_22094920
wiley_primary_10_1002_bit_24377_BIT24377
istex_primary_ark_67375_WNG_SKZSPK75_T
PublicationCentury 2000
PublicationDate April 2012
PublicationDateYYYYMMDD 2012-04-01
PublicationDate_xml – month: 04
  year: 2012
  text: April 2012
PublicationDecade 2010
PublicationPlace Hoboken
PublicationPlace_xml – name: Hoboken
– name: United States
– name: New York
PublicationTitle Biotechnology and bioengineering
PublicationTitleAlternate Biotechnol. Bioeng
PublicationYear 2012
Publisher Wiley Subscription Services, Inc., A Wiley Company
Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc., A Wiley Company
– name: Wiley Subscription Services, Inc
References Kanai S, Liu J, Patapoff TW, Shire SJ. 2008. Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity. J Pharm Sci 97(10): 4219-4227.
Teske CA, Lebreton B, van Reis R. Inline ultrafiltration. Biotechnol Prog 26(4): 1068-1072.
van Reis R, Zydney A. 2007. Bioprocess membrane technology. J Membr Sci 297: 16-30.
Pacis E. 2010. Systematic approaches to develop chemically defined cell culture feed media. Biopharm Int 23(11): 22.
Kelley B. 2007. Very large scale monoclonal antibody purification: The case for conventional unit operations. Biotechnol Progress 23: 995-1008.
Low D, Leary RO, Pujar NS. 2007. Future of antibody purification. J Chromatogr B 848: 48-63.
Kamerzell TJ, Kanai S, Liu J, Shire SJ, Wang YJ. 2009. Increasing IgG concentration modulates the conformational heterogeneity and bonding network that influence solution properties. J Phys Chem B 113(17): 6109-6118.
2010; 23
2009; 113
26
2008; 97
2007; 848
2007; 23
2007; 297
e_1_2_7_6_1
e_1_2_7_5_1
e_1_2_7_4_1
e_1_2_7_3_1
e_1_2_7_9_1
Teske CA (e_1_2_7_8_1); 26
e_1_2_7_2_1
Pacis E (e_1_2_7_7_1) 2010; 23
References_xml – volume: 97
  start-page: 4219
  issue: 10
  year: 2008
  end-page: 4227
  article-title: Reversible self‐association of a concentrated monoclonal antibody solution mediated by Fab‐Fab interaction that impacts solution viscosity
  publication-title: J Pharm Sci
– volume: 26
  start-page: 1068
  issue: 4
  end-page: 1072
  article-title: Inline ultrafiltration
  publication-title: Biotechnol Prog
– volume: 297
  start-page: 16
  year: 2007
  end-page: 30
  article-title: Bioprocess membrane technology
  publication-title: J Membr Sci
– volume: 113
  start-page: 6109
  issue: 17
  year: 2009
  end-page: 6118
  article-title: Increasing IgG concentration modulates the conformational heterogeneity and bonding network that influence solution properties
  publication-title: J Phys Chem B
– volume: 23
  start-page: 22
  issue: 11
  year: 2010
  article-title: Systematic approaches to develop chemically defined cell culture feed media
  publication-title: Biopharm Int
– volume: 848
  start-page: 48
  year: 2007
  end-page: 63
  article-title: Future of antibody purification
  publication-title: J Chromatogr B
– volume: 23
  start-page: 995
  year: 2007
  end-page: 1008
  article-title: Very large scale monoclonal antibody purification: The case for conventional unit operations
  publication-title: Biotechnol Progress
– volume: 23
  start-page: 22
  issue: 11
  year: 2010
  ident: e_1_2_7_7_1
  article-title: Systematic approaches to develop chemically defined cell culture feed media
  publication-title: Biopharm Int
  contributor:
    fullname: Pacis E
– volume: 26
  start-page: 1068
  issue: 4
  ident: e_1_2_7_8_1
  article-title: Inline ultrafiltration
  publication-title: Biotechnol Prog
  doi: 10.1002/btpr.404
  contributor:
    fullname: Teske CA
– ident: e_1_2_7_3_1
  doi: 10.1021/jp9001548
– ident: e_1_2_7_9_1
  doi: 10.1016/j.memsci.2007.02.045
– ident: e_1_2_7_2_1
– ident: e_1_2_7_5_1
  doi: 10.1021/bp070117s
– ident: e_1_2_7_6_1
  doi: 10.1016/j.jchromb.2006.10.033
– ident: e_1_2_7_4_1
  doi: 10.1002/jps.21322
SSID ssj0007866
Score 2.3547823
Snippet As the therapeutic monoclonal antibody (mAb) market continues to grow, optimizing production processes is becoming more critical in improving efficiencies and...
Abstract As the therapeutic monoclonal antibody (mAb) market continues to grow, optimizing production processes is becoming more critical in improving...
SourceID proquest
crossref
pubmed
wiley
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 962
SubjectTerms Animals
Antibodies, Monoclonal - biosynthesis
Antibodies, Monoclonal - genetics
Antibodies, Monoclonal - isolation & purification
antibody purification
Batch Cell Culture Techniques - instrumentation
Batch Cell Culture Techniques - methods
Bioreactors
Biotechnology
Bottlenecks
Cell culture
CHO Cells
Chromatography, High Pressure Liquid
concentration factor
Cricetinae
Cricetulus
Equipment Design
Filtration - methods
Monoclonal antibodies
Nephelometry and Turbidimetry
Osmolar Concentration
Pressure
process debottleneck
Proteins
Recombinant Fusion Proteins - biosynthesis
Recombinant Fusion Proteins - isolation & purification
Rheology
Single Pass TFF (SPTFF)
Spectrophotometry, Ultraviolet
Tangential Flow Filtration (TFF)
ultrafiltration
Title Single pass tangential flow filtration to debottleneck downstream processing for therapeutic antibody production
URI https://api.istex.fr/ark:/67375/WNG-SKZSPK75-T/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fbit.24377
https://www.ncbi.nlm.nih.gov/pubmed/22094920
https://www.proquest.com/docview/926801384
https://search.proquest.com/docview/1434025311
https://search.proquest.com/docview/923574796
Volume 109
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ha9QwFH-Miagfpt7U1alEkeGX3npp0yT4aZvO6XCId8MxhJI2KRx3a49dD51_vS_JtdvEgfipLU1Lm7yX_H7Je78AvNYIiQdMq5ByFYfY-0XoUkyEUZGUQqQyKQs7D_n5KD04Tj6dsJMVeNvmwnh9iG7CzXqG66-tg6t8vn0pGpqPm75V07OZ5IOY23Cud18vpaO48OuUljHHTNJWVSii292T18aiW7Zaf_4NaF7HrW7g2b8P39tP9vEmk_6iyfvFrz_UHP_znx7A2hKQkh1vQQ9hxVQ9WN-pkIyfXZAt4kJE3dx7D27vtmd39tqN4npw74qm4TrMhniYGjJDVE4a5VK30MZJOa1_kHI8Xcr0kqYm2th9zHDYM8WEaDvNbcPez8jMJy_gewhCanIlRYygHYzzWl_YMtoL3z6C4_33o72DcLmtQ1gkSF9ChSyUSqROwiAY09xoqpU2RZwmguYmF5a0SR6puGCKlwWOnkarQcpkykqFXdJjWK3qymwA0VwlUSzxvWWU5CwXSkpuSs7wOoq1COBV28DZzKt3ZF6nmWZY15mr6wC2XNN3JdT5xIa7cZZ9O_qQDQ9Ph18O8WIUwGZrG9nS0-eZpKmwq71JAC-7u9gAdt1FVaZezJFdxcjSsbMbBEBuKCOt7FDCZRrAE2913edQihRc0iiAN852bv6TbPfjyJ08_feim3AXMSD1wUjPYLU5X5jniLOa_IVzqN88DyOB
link.rule.ids 315,783,787,1378,27936,27937,46306,46730
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFD4am9DGA5eOQRgXg9C0l3Spc7Et8bINRke3CtFOTEjIcmJHqtql1ZYKxq_n2GmyDTEJ8ZREcaLEPsf-vuPjzwBvNULiTqyVT5kKfez9AnSpmPtBFuWcJyLKMxuHPO4n3ZPo02l8ugTv6rUwlT5EE3CznuH6a-vgNiC9c6Uamo7KtpXTY3dgBd09tBs3vP9yJR7FeDVTaTlzGAta6woFdKd59MZotGIr9uffoOZN5OqGnoMH8L3-6CrjZNyel2k7-_WHnuP__tVDuL_ApGS3MqJHsGSKFqzvFsjHzy7JFnFZoi783oK7e_XZ6n69V1wL7l2TNVyH2QAPE0NmCMxJqdzqLTRzkk-mP0g-miyUekk5JdrYrcxw5DPZmGgb6baZ72dkVq1fwPcQRNXk2ioxgqYwSqf60pbRlfbtYzg5-DDc7_qLnR38LEIG4yskolQge-IG8ZhmRlOttMnCJOI0NSm3vE2wQIVZrFie4QBqtOoksUjiXGGvtAHLxbQwT4FopqIgFPjePIjSOOVKCGZyFuN1EGruwZu6heWsEvCQlVQzlVjX0tW1B1uu7ZsS6nxsM95YLL_2P8pB79vgcw8vhh5s1sYhF85-IQVNuJ3wjTx43dzFBrBTL6ow0_kFEqwQiTr2dx0PyC1lhFUeiphIPHhSmV3zOZQiCxc08GDbGc_tfyL3Dofu5Nm_F30Fq93h8ZE8Ouz3NmENISGtcpOew3J5PjcvEHaV6UvnXb8BTBQnmQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFD4am7g9cOm4hHExCE28pEudi23xtA3KRqGaaCcmhGQ5sSNV7ZJoSwXj13McN92GmIR4iq04UWKfY3-fffwZ4LVGSNyLtfIpU6GPvV-ALhVzP8iinPNERHlm5yE_D5O9w-jjUXy0Am_bvTBOH2I54WY9o-mvrYNXOt86Fw1NJ3XXqumxa7AWJYh8LSL6cq4dxbhbqLSUOYwFbWWFArq1fPTSYLRm6_Xn35DmZeDajDz9u_C9_WYXcDLtzuu0m_36Q87xP3_qHtxZIFKy7UzoPqyYogPr2wWy8eMzskmaGNFm8r0D13fa1M3d9qS4Dty-IGq4DtUILzNDKoTlpFbN3i00cpLPyh8kn8wWOr2kLok29iAzHPdMNiXaznPbuPdjUrndC_gegpiaXNgjRtAQJmmpz2wZ7ZRvH8Bh__14d89fnOvgZxHyF18hDaUCuRM3iMY0M5pqpU0WJhGnqUm5ZW2CBSrMYsXyDIdPo1UviUUS5wr7pIewWpSFeQxEMxUFocD35kGUxilXQjCTsxjzQai5B6_aBpaVk--QTqiZSqxr2dS1B5tN0y9LqJOpjXdjsfw6_CBHg2-jgwFmxh5stLYhF65-KgVNuF3ujTx4ubyLDWAXXlRhyvkp0qsQaTr2dj0PyBVlhNUdiphIPHjkrG75OZQiBxc08OBNYztX_4nc2R83iSf_XvQF3Dh415ef9oeDDbiFeJC6wKSnsFqfzM0zxFx1-rzxrd-7aiZI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Single+pass+tangential+flow+filtration+to+debottleneck+downstream+processing+for+therapeutic+antibody+production&rft.jtitle=Biotechnology+and+bioengineering&rft.au=Dizon-Maspat%2C+Jemelle&rft.au=Bourret%2C+Justin&rft.au=D%27Agostini%2C+Anna&rft.au=Li%2C+Feng&rft.date=2012-04-01&rft.pub=Wiley+Subscription+Services%2C+Inc.%2C+A+Wiley+Company&rft.issn=0006-3592&rft.eissn=1097-0290&rft.volume=109&rft.issue=4&rft.spage=962&rft.epage=970&rft_id=info:doi/10.1002%2Fbit.24377&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_WNG_SKZSPK75_T
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-3592&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-3592&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-3592&client=summon